T-cell agonists in cancer immunotherapy by Gennaro Ciliberto, Aung Naing, Joud Hajjar, Cara L Haymaker, Yeonjoo Choi, Yaoyao Shi

Get full text

The Natural History of X-Linked Lymphoproliferative Disease (XLP1): Lessons from a Long-Term Survivor by Yike Jiang, Mihail Firan, Sarada L. Nandiwada, Anaid Reyes, Rebecca A. Marsh, Tiphanie P. Vogel, Joud Hajjar

Get full text

Strategies for improving the management of immune-related adverse events by James L Gulley, Patrick Hwu, Gennaro Ciliberto, Aung Naing, Funda Meric-Bernstam, Michael B Atkins, Joud Hajjar

Get full text

Histologic and immune characterization of cutaneous immune-related adverse events induced by immune checkpoint inhibitors by Jonathan L Curry, Aung Naing, Joud Hajjar, Cara L Haymaker, Ken Chen, Dzifa Yawa Duose, Anisha B Patel, Omar Pacha, Nejla Ozirmak Lermi

Get full text

Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors by Sinchita Roy-Chowdhuri, Ravi Murthy, Aung Naing, Joud Hajjar, Kenneth R Hess, Coya Tapia, Phyu P. Aung, Mingxuan Xu, Fengying Ouyang, Anas Alshawa, Gopal Singh, Vincent Yang, Lilibeth Castillo, Hung Le, Bettzy Stephen, Ignacio Wistuba

Get full text